Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer

European Journal of Surgical Oncology

Volumn 37, Issue 9, 2011, Pages 737-746

  Hompes, D ^a   Ruers, T ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Bevacizumab; Complications; Metastatic colorectal cancer; Non surgical; Surgical

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL BLEEDING; ABSCESS; ANASTOMOSIS DEHISCENCE; ANASTOMOSIS LEAKAGE; BILE LEAKAGE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY SURGERY; HEART DISEASE; HEMATOMA; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; INTESTINE PERFORATION; LEUKOPENIA; LIVER DISEASE; MEDLINE; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; SEPSIS; SUBPHRENIC ABSCESS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 80051669505     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.06.004     Document Type: Review

References (40)

1. T. Shih, and C. Lindley Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin Therap 28 2006 1779 1802 (Pubitemid 46038527)
2. A. Wagner, D. Arnold, and A. Grothey Anti-angiogenic therapy for metastatic colorectal cancer Cochrane Database Syst Rev 8 3 2009 CD005392
3. D. McDonald, and P. Baluk Significance of blood vessel leakiness in cancer Cancer Res 62 2002 5381 5385 (Pubitemid 35024617)
4. Y. Cao, W. Zhong, and Y. Sun Improvement of angiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance Semin Cancer Biol 2009 may 27 [Epub ahead of print]
5. M. Los, J. Roodhart, and E. Voest Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer The Oncologist 12 2007 443 450 (Pubitemid 46698722)
6. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147 (Pubitemid 38524883)
7. B. Nordlinger, E. Van Cutsem, and T. Gruenberger Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Ann Oncol 20 2009 985 992
8. M. Klinger, S. Eipeldauer, and T. Gruenberger Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant xelox/folfox therapy of colorectal cancer liver metastases Eur J Surg Oncol 35 2009 515 520
9. D. Schiff, P. Wen, and M. van den Brent Neurological adverse effects caused by cytotoxic and targeted therapies Nat Rev Clin Oncol 6 2009 596 603
10. R. Kelly, B. Billemont, and O. Rixe Renal toxicity of targeted therapies Target Oncol 4 2009 121 133
11. D. Ribero, H. Wang, and J. Vauthey Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer 110 2007 2761 2767 (Pubitemid 350250347)
12. M. Fakih, and J. Lombardo Bevacizumab-induced nasal septum perforation The Oncologist 11 2006 85 86
13. S. Nalluri, D. Chu, and R. Keresztes Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
14. L. Ellis, S. Curley, and A. Grothey Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab J Clin Oncol 23 2005 4853 4855 (Pubitemid 46223989)
15. M. Gordon, K. Margolin, and M. Talpaz Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 2001 843 850 (Pubitemid 32119100)
16. D. Bose, F. Meric-Bernstam, and W. Hofstetter Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care Lancet Oncol 11 2010 373 382
17. Infobrochure Roche: Avastin.
18. C. Allegra, G. Yothers, and M. O'Connell Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer J Clin Oncol 27 2009 3385 3390
19. L. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
20. F. Kabbinavar, H. Hurwitz, and O. Rosen Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials J Clin Oncol 27 2009 199 205
21. H. Hochster, L. Hart, and E. Hedrick Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 2008 3523 3529
22. B. Giantonio, P. Catalano, and N. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544 (Pubitemid 46733080)
23. F. Kabbinavar, J. Schulz, and W. Novotny Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 2005 3697 3705
24. F. Kabbinavar, J. Hambleton, and H. Hurwitz Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 2005 3706 3712
25. H. Hurwitz, L. Fehrenbacher, and F. Kabbinavar Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
26. B. Gruenberger, D. Tamandl, and T. Gruenberger Bevacizumab, capecitabine and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J Clin Oncol 26 2008 1830 1835
27. E. Van Cutsem, F. Rivera, and D. Cunningham Safety and efficacy of first-line bevacizumab with folfox, xelox, folfiri and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 2009 1842 1847
28. M. Kozloff, M. Yood, and A. Grothey Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study The Oncologist 14 2009 862 870
29. D. Blazer, Y. Kishi, and N. Vauthey Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases J Clin Oncol 25 2008 5344 5351
30. G. Poultsides, E. Servais, and L. Saltz Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving chemotherapy without surgery as initial treatment J Clin Oncol 27 2009 3379 3384
31. F. Kabbinavar, H. Hurwitz, and L. Fehrenbacher Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin(LV) with 5FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
32. S. Hapani, D. Chu, and S. Wu Risk of gastrointestinal perforation in perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol 10 2009 559 568
33. F. Scappaticci, L. Fehrenbacher, and H. Hurwitz Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab J Surg Oncol 91 2005 173 180 (Pubitemid 41254420)
34. N. Wolmark, G. Yothers, and M. O'Connell A phase III trialcomparing mFolfox6 to mFolfox plus bevacizumab in stage II and III carcinoma of the colon: results of NSABP protocol C-08 Proc Am Soc Clin Oncol 27 2009 abstr LBA4
35. T. Gruenberger, B. Gruenberger, and W. Scheithauer Neoadjuvant therapy with bevacizumab J Clin Oncol 24 2006 2592 2593
36. C.G. Willett, Y. Boucher, and D. Duda Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J Clin Oncol 23 2005 8136 8139 (Pubitemid 46657433)
37. W. Zawacki, G. Walker, and E. DeVasher Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy J Vasc Interv Radiol 20 2009 624 627
38. S. Kesmodel, L. Ellis, and E. Lin Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases J Clin Oncol 26 2008 5254 5260
39. S. Reddy, M. Morse, and H. Hurwitz Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases J Am Coll Surg 206 2008 96 106 (Pubitemid 350267242)
40. M. D'Angelica, P. Kornprat, and L. Saltz Lack of evidence for increased morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study Ann Surg Oncol 14 2007 759 765 (Pubitemid 46175324)